1-20 of 81
palbociclib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A common protein target for an uncommon subtype of AML

Martin Carroll
Journal: Blood
Blood (2020) 136 (4): 377–378.
https://doi.org/10.1182/blood.2020006487
Published: 2020
Journal Articles

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

Marco De Dominici, Patrizia Porazzi, Youcai Xiao, Allen Chao, Hsin-Yao Tang, Gaurav Kumar, Paolo Fortina, Orietta Spinelli, Alessandro Rambaldi, Luke F. Peterson, Svetlana Petruk, Camilla Barletta, Alexander Mazo, Gino Cingolani, Joseph M. Salvino, Bruno Calabretta
Journal: Blood
Blood (2020) 135 (18): 1560–1573.
https://doi.org/10.1182/blood.2019003604
Published: 2020
Includes: Supplemental data
Journal Articles

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Christina Y. Lee, MD, Kevin Wang, B.S., Nancy L. Bartlett, MD, LeAnn Ridling, Kristie A. Blum, MD, Kami J. Maddocks, MD, Steven I Park, MD, Jia Ruan, MD PhD, Kenneth Eng, B.S., Lorenzo Galluzzi, PhD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1492.
https://doi.org/10.1182/blood-2019-130944
Published: 2019
Journal Articles

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

Nicole Zhao, Maurizio Di Liberto, PhD, Olivier Elemento, PhD, Selina Chen-Kiang, PhD, Xiangao Huang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 299.
https://doi.org/10.1182/blood-2019-128927
Published: 2019
Journal Articles

Targeting Hypersumoylation in Mantle Cell Lymphoma

Walter Hanel, MD PhD, Liudmyla Tsyba, PhD, Dennis Huszar, PhD, Alex Prouty, Xiaoli Zhang, PhD, JoBeth Helmig-Mason, Msc, Bethany L Mundy-Bosse, PhD, Youssef Youssef, MD, Samir Parekh, MD, Kami J. Maddocks, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4060.
https://doi.org/10.1182/blood-2019-127363
Published: 2019
Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa
Journal: Blood
Blood (2019) 134 (Supplement_1): 3781.
https://doi.org/10.1182/blood-2019-124670
Published: 2019
Journal Articles

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Christina Y. Lee, MD, Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Nancy L Bartlett, MD, Kami J. Maddocks, MD, John P. Leonard, MD, Nils-Petter Rudqvist, PhD, Lorenzo Galluzzi, PhD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3973.
https://doi.org/10.1182/blood-2019-122322
Published: 2019
Journal Articles

CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis

Veronika Sexl, MD PhD, Karoline Kollmann, PhD, Florian Bellutti
Journal: Blood
Blood (2019) 134 (Supplement_1): SCI-15.
https://doi.org/10.1182/blood-2019-121101
Published: 2019
Journal Articles

Quantitative Proteomic Analysis of Relapsed Multiple Myeloma Identifies CDK6 Upregulation As a Potential Targetable Resistance Mechanism for Lenalidomide

Yuen Lam Dora Ng, Stephan Bohl, Evelyn Ramberger, Oliver Popp, Imke Bauhuf, Anna Dolnik, Christian Steinebach, Michael Gütschow, Lars Bullinger, Philipp Mertins, Jan Kroenke
Journal: Blood
Blood (2019) 134 (Supplement_1): 2567.
https://doi.org/10.1182/blood-2019-130682
Published: 2019
Journal Articles

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

Golam Mohi, PhD, Avik Dutta, PhD, Dipmoy Nath, PhD, Yue Yang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4200.
https://doi.org/10.1182/blood-2019-132038
Published: 2019
Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood
Blood (2019) 134 (Supplement_1): 878.
https://doi.org/10.1182/blood-2019-126020
Published: 2019
Journal Articles

Martin P, Bartlett NL, Blum KA, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood . 2019;133(11):1201-1204.

Journal: Blood
Blood (2019) 134 (11): 908.
https://doi.org/10.1182/blood.2019002741
Published: 2019
Journal Articles

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Clinical Trials & Observations Brief Report
Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven Park, Kami Maddocks, Jia Ruan, LeAnn Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio Inghirami, Maurizio DiLiberto, Selina Chen-Kiang, John P. Leonard
Journal: Blood
Blood (2019) 133 (11): 1201–1204.
https://doi.org/10.1182/blood-2018-11-886457
Published: 2019
Journal Articles

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Christopher B. Benton, MD, William G. Wierda, MD PhD, Prithviraj Bose, MD, Musa E. Yilmaz, MD, Elias J. Jabbour, MD, Steven M. Kornblau, MD, Kapil N. Bhalla, MD, Naveen Pemmaraju, MD, Nitin Jain, MD, Rashmi Malla, RN, BSN, Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4057.
https://doi.org/10.1182/blood-2018-99-117334
Published: 2018
Journal Articles

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Stephen E Kurtz, PhD, Christopher A. Eide, Narain P. Dubey, Andy Kaempf, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Anupriya Agarwal, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2726.
https://doi.org/10.1182/blood-2018-99-117537
Published: 2018
Journal Articles

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Mathias A. Schneeweiss, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Mohamad Jawhar, Greiner Georg, MD PhD, Gregor Hoermann, Wolfgang R. Sperr, Michel Arock, Andreas Reiter, MD, Peter Valent, Karoline V. Gleixner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1363.
https://doi.org/10.1182/blood-2018-99-116525
Published: 2018
Journal Articles

Enhanced Selective Inhibition of KRAS Mutant Hematopoietic Progenitor Cell Expansion By MEK and Bcl-2 Inhibition

Huan-Ting Lin, PhD, Kenji Kubara, Kazuto Yamazaki, PhD, Masatoshi Takagi, MD PhD, Takuya Naruto, MD PhD, Tomohiro Morio, MD PhD, Takashi Okumura, PhD, Makoto Otsu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1278.
https://doi.org/10.1182/blood-2018-99-117889
Published: 2018
Journal Articles

Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Muhammad Jahanzeb Khalil, MD, Faisal Mahfooz, MD, Madeeha Shafqat, Anum Qureshi, Insija Ilyas Selene, MBBS, Syed Shabee Hassan, MD, Muhammad Junaid Tariq, MD, Muhammad Yasir, MD, Sharoon Samuel, MBBS, Maryam Sadiq, MBBS, Faiz Anwer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1950.
https://doi.org/10.1182/blood-2018-99-111587
Published: 2018
Journal Articles

Recurrent Genomic Aberrations of D-Type Cyclins Are Therapeutic Targets of CDK4/6 Inhibitors in t(8;21) and MLL -Rearranged Acute Myeloid Leukemia

Hidemasa Matsuo, PhD, Kenichi Yoshida, MD PhD, Kazutaka Fukumura, PhD, Kana Nakatani, Yuki Noguchi, Saho Takasaki, Mina Noura, Yusuke Shiozawa, MD, PhD, Yuichi Shiraishi, PhD, Kenichi Chiba, PhD, Hiroko Tanaka, BA, Ai Okada, Yasuhito Nannya, MD PhD, June Takeda, MD, Hiroo Ueno, MD, Norio Shiba, MD PhD, Genki Yamato, MD PhD, Nobutaka Kiyokawa, MD PhD, Daisuke Tomizawa, MD PhD, Takashi Taga, MD PhD, Akio Tawa, MD PhD, Yasuhide Hayashi, MD PhD, Hiroyuki Mano, MD, PhD, Satoru Miyano, PhD, Yasuhiko Kamikubo, MD, PhD, Seishi Ogawa, MD PhD, Souichi Adachi, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2797.
https://doi.org/10.1182/blood-2018-99-111073
Published: 2018
Journal Articles

Targeting Distinct Promoter- and Enhancer-Driven Dependencies in Multiple Myeloma

Chandraditya Chakraborty, PhD, Mehmet Kemal Samur, PhD, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3156.
https://doi.org/10.1182/blood-2018-99-112583
Published: 2018